Literature DB >> 1197884

Prevention of myocardial generation in hamsters with hereditary cardiomyopathy.

G Jasmin, E Bajusz.   

Abstract

A number of drugs have been tested for their ability to prevent or change the course of skeletal and heart lesions occurring with a 100% incidence in cardiomyopathic hamsters (UM-X7.1). These drugs were selected because they act either on the metabolism or turnover of Ca or on adrenergic receptors. Verapamil (Isoptin), a potent inhibitor of myocardial transmembrane Ca conductivity, was found to completely prevent the myocardial lesions in myopathic hamsters. The hamsters were 28 to 30 days of age at the beginning of the experiment and were injected subcutaneously twice daily during 30 consecutive days in doses of 0.5 mg during the first week and 0.75 mg during the subsequent weeks. The protection afforded by Verapamil was no longer evident 30 days after interruption of the treatment. The severity of both cardiac and skeletal muscle lesions was found significantly lowered in hamsters receiving Dibenamine. It is assumed that Verapamil acts mainly by preventing excessive calcium influx in cardiomyocytes, whereas Dibenamine improves the microcirculation, which is deficient during the necrotizing phase of the polymyopathy. The latter assumption rests on the fact that, in myopathic hamsters, the reactivity pattern of alkaline phosphatase is altered at the level of the capillaries of cardiac and skeletal muscles.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1197884

Source DB:  PubMed          Journal:  Recent Adv Stud Cardiac Struct Metab        ISSN: 0363-5872


  4 in total

1.  Cardioprotection by oxyfedrine in hereditary cardiomyopathic hamsters.

Authors:  K Lossnitzer; A Konrad; W Mohr; M Jakob; F Stroman
Journal:  Basic Res Cardiol       Date:  1979 Nov-Dec       Impact factor: 17.165

2.  Prevention by cromakalim of spontaneously occurring cardiac necroses in polymyopathic hamsters.

Authors:  G Jasmin; L Proschek
Journal:  Cardiovasc Drugs Ther       Date:  1996-11       Impact factor: 3.727

3.  δ-Sarcoglycan-deficient muscular dystrophy: from discovery to therapeutic approaches.

Authors:  Alison M Blain; Volker W Straub
Journal:  Skelet Muscle       Date:  2011-03-17       Impact factor: 4.912

4.  Modulation of Vascular ACE by Oxidative Stress in Young Syrian Cardiomyopathic Hamsters: Therapeutic Implications.

Authors:  Nildris Cruz; Jorge D Miranda; Maria J Crespo
Journal:  J Clin Med       Date:  2016-07-13       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.